News | July 24, 2009

World’s First Cardiac Adult Stem Cell Patient Receives Infusion Trial in Louisville

Dr. Mark Slaughter with patient Michael Jones, the first recipient of adult stem cells for myocardial regeneration.

July 24, 2009 – Michael Jones has become the world’s first recipient of adult cardiac stem cells to treat congestive heart failure. Jones’ infusion on July 17 marks the world’s first phase-one, FDA-approved clinical trial using c-kit-positive cardiac stem cells to treat heart disease being conducted by a team of University of Louisville physicians at Jewish Hospital.

During the infusion procedure, Jones was directly injected with his own cardiac stem cells into heart scar tissue using a minimally-invasive cardiac catheterization procedure. The 66-year-old, self-employed man continues to recover following the outpatient procedure.

Mark Slaughter, M.D., chief of the division of cardiothoracic surgery at University of Louisville and director of the Heart Transplant and Mechanical Assist Device Program at Jewish Hospital, performed coronary artery bypass surgery on Jones on March 23. Jones suffered from congestive heart failure due to multiple blocked arteries that had resulted in permanent scarring of his heart muscle. During the procedure, Jones’ cardiac stem cells were retrieved from a portion of his own atrium, the upper chamber of the heart. The tissue was then sent to Piero Anversa, of Harvard University and Brigham & Women’s Hospital in Boston, for processing and to grow cardiac stem cells from Jones’ tissue.

Jones’ infusion procedure was performed at Jewish Hospital by Sohail Ikram, M.D., University of Louisville professor of medicine and director and chief of invasive and interventional cardiology at Jewish Hospital.

“We continue to enroll patients in this first-of-its-kind clinical trial,” said study leader Roberto Bolli, Jewish Hospital Heart and Lung Institute distinguished chair in cardiology and director of University of Louisville’s Institute for Molecular Cardiology. “We hope to help the heart regenerate its own tissue and improve heart function.”

Bolli is collaborating with a number of leaders in the field of cardiovascular and stem cell medicine for this clinical trial. The team will continue to evaluate Jones, as well as other patients who have enrolled in the clinical trial, for heart function and blood flow. In addition, the heart’s overall size and the size of the scar tissue will be measured.

Since this is a phase-one clinical trial designed to test the treatment’s safety and feasibility, all patients enrolled in the trial will receive the cardiac stem cell therapy.

Bolli said a similar stem cell clinical trial is being conducted at another facility in California. "The difference between what we have done and what another institute nationally has done is that we have injected a pure population of stem cells, the c-kit-positive cells. The other institution injected cardiosphere-derived cells, which are a mixture of primitive and partially differentiated cells, complicating the recognition of the actual therapeutic cell. Our study involves a specific, well-characterized population of undifferentiated cells: the c-kit-positive cardiac stem cells are self-renewing, clonogenic and multipotent, which are the fundamental properties of stem cells," Bolli said.

For more information: www.jewishhospital.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Overlay Init